4-Chloro-6-iodoquinazoline

We are 4-Chloro-6-iodoquinazoline CAS:98556-31-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-Chloro-6-iodoquinazoline
CAS.NO:98556-31-1
Synonyms:4-Chloro-6-iodoquinazoline
6-iodo-4-chloroquinazoline
4-chloro-6-iodo-4-quinazoline
4-chloro-6-iodo-quinazoline
 
Physical and Chemical Properties:
Density 2.0±0.1 g/cm3
Boiling Point 363.2±22.0 °C at 760 mmHg
Molecular Formula C8H4ClIN2
Molecular Weight 290.488
Flash Point 173.4±22.3 °C
 
Specification:
Appearance:Off-white to grey powder
Assay:≥95.0%
Loss on drying:≤1.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Lapatinib(CAS:231277-92-2) and Lapatinib ditosylate(CAS:388082-78-8).

4-Chloro-6-iodoquinazoline


Related News: Corden Pharma group companies offer contract development and contract manufacturing for advanced pharmaceutical intermediates, APIs, and drug product formulations with more than 1,500 individuals supporting their customers with specialized technologies in all international markets.Methyl 2-methyl-2-phenylpropanoate Corden Pharma group companies offer contract development and contract manufacturing for advanced pharmaceutical intermediates, APIs, and drug product formulations with more than 1,500 individuals supporting their customers with specialized technologies in all international markets.2-hidroxi-6-cloroquinoxalina CAS:2427-71-6 In addition to APIs, a variety of pharmaceutical excipients are contained in the medicine.Decil (trimetoxi) silano CAS:5575-48-4 “With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.”“With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.”

Related Products
Product Name
2′,3′,5′-Tri-O-acetyl-2-fluoroadenosine View Details
3-Chloro-4-Fluorobenzyl Cyanide View Details
4-Bromo-3-nitrotoluene View Details
9-Anthraceneboronic Acid manufacturer Methyl 6-methylnicotinate manufacturer 4-[(3-fluorophenyl)methoxy]benzaldehyde manufacturer 5-Nitroindole manufacturer 2,4,5-Trichloropyrimidine manufacturer